AIOS replicates Bolt playbook across Europe

This plan turns regulation from a barrier into AIOS's main expansion tool. In Europe, an obesity telehealth company cannot just turn on ads and ship drugs across borders. It needs a local clinical and pharmacy stack in each country. Buying a licensed pharmacy is the shortcut. Bolt showed that once the license and fulfillment are local, AIOS can reuse the same intake flow, clinician workflow, refill logic, and paid acquisition engine that already worked in the UK.

• The UK Bolt deal was proof that the model can restart growth after the US compounded GLP-1 shutdown. AIOS used Bolt to sell branded Wegovy and Mounjaro into a rationed private pay market, and scaled to about 150,000 patients with branded drug revenue largely passed through to Lilly and Novo.
  1 sacra
• The reason to buy local pharmacies instead of building greenfield is speed through licensing and localization. Hims & Hers used the same logic when it agreed to acquire ZAVA in June 2025, using one deal to deepen the UK and enter Germany, France, and Ireland.
  3 hims 4 hims
• Price is the wedge because branded GLP-1 prices are partly manufacturer set and visible across the market. Boots and Numan both price Wegovy by dose, while Numan notes manufacturer changes drive private pricing. That makes a low markup pharmacy strategy easy for customers to compare and hard for slower incumbents to ignore.
  5 boots 6 numan 7 numan

The next step is a Europe wide network where local pharmacy assets handle compliance and dispensing, while one shared software and growth layer drives demand across countries. If AIOS keeps adding markets this way, it can become the lowest cost branded GLP-1 distributor in Europe first, then add much more margin when generic semaglutide arrives in the early 2030s.